GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results